Skip to main content

Table 4 Comparison between patients receiving Enzalutamid and those receiving placebo on health-related quality of life by applying the Improved RIDIT analysis to data from Devlin et al. [14]

From: Improved RIDIT statistic approach provides more intuitive and informative interpretation of EQ-5D data

Placebo vs Enzalutamid Improved RIDIT Chi-square
Week 13 \( {\hat{\pi}}^{-} \) \( {\hat{\pi}}^0 \) \( {\hat{\pi}}^{+} \) ARR [95% CI] Odds ordinal [95% CI] PBH-value PBH-value (a)
 Mobility 0.218 0.602 0.181 0.036 [− 0.011; 0.082] 1.12 [0.98; 1.47] 0.254 0.319 (0.319)
 Self Care 0.075 0.868 0.057 0.018 [−0.009; 0.045] 1.31 [0.94; 1.83] 0.167 0.450 (0.225)
 Usual Activities 0.227 0.592 0.180 0.047 [0.000; 0.094] 1.26 [1.04; 1.53] 0.175 0.204 (0.068)
 Pain/Discomfort 0.301 0.487 0.212 0.089 [0.037; 0.142] 1.42 [1.21; 1.67] 0.007 0.025 (0.005)
 Anxiety/Depression 0.248 0.579 0.173 0.075 [0.027; 0.122] 1.43 [1.19; 1.71] 0.013 0.024 (0.006)
Week 25
 Mobility 0.215 0.597 0.188 0.027 [−0.029; 0.082] 1.14 [0.89; 1.47] 0.257 0.582 (0.582)
 Self Care 0.092 0.850 0.058 0.034 [0.001; 0.067] 1.58 [1.11; 2.26] 0.157 0.309 (0.103)
 Usual Activities 0.223 0.616 0.161 0.062 [0.008; 0.116] 1.39 [1.10; 1.75] 0.124 0.104 (0.026)
 Pain/Discomfort 0.296 0.498 0.206 0.091 [0.029; 0.153] 1.44 [1.19; 1.75] 0.033 0.080 (0.016)
 Anxiety/Depression 0.223 0.607 0.170 0.053 [−0.002; 0.108] 1.31 [1.04; 1.66] 0.132 0.322 (0.161)
  1. CI Confidence Interval, aP-values calculated in [14] using the chi-square test to compare between the placebo and Enzalutamid groups basing on the percentage of patients with (2 or 3) or without (1) problems in each EQ-5D dimension. PBH-value the Bonferroni-Holm p-values correction